Wellington Biomedical Innovation Master Investors (Cayman) I L.P. - Jun 21, 2021 Form 4 Insider Report for Verve Therapeutics, Inc. (VERV)

Role: 10%+ Owner
Signature: /s/ Wellington Biomedical Innovation Master Investors (Cayman) I L.P., By: Wellington Management Company LLP, as Investment Adviser, /s/ Peter McIsaac, Title: Authorized Person
Stock symbol: VERV
Transactions as of: Jun 21, 2021
Transactions value $: $0
Form type: 4
Date filed: 6/22/2021, 05:14 PM
Previous filing: Jun 16, 2021
Next filing: Jul 28, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VERV	Common Stock	Conversion of derivative security		+1.34M			1.34M	Jun 21, 2021	Direct	F1
transaction	VERV	Common Stock	Conversion of derivative security		+1.15M	+85.81%		2.5M	Jun 21, 2021	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VERV	Series A-2 Preferred Stock	Conversion of derivative security		-12.4M	-100%		0	Jun 21, 2021	Common Stock	1.34M		Direct	F1
transaction	VERV	Series B Preferred Stock	Conversion of derivative security		-10.7M	-100%		0	Jun 21, 2021	Common Stock	1.15M		Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Wellington Biomedical Innovation Master Investors (Cayman) I L.P. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	The Series A-2 Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on an approximately 9.2595:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series A-2 Preferred Stock had no expiration date.
F2	The Series B Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on an approximately 9.2595:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date.